DGAP-News: MediClin AG
/ Key word(s): Half Year Results
Offenburg, 29 July 2022 Consolidated sales for the first half of 2022 up 10% on the previous pandemic figure – no change in forecast Rising demand for the medical, therapeutic and nursing care services of MEDICLIN raised sales and earnings within the Group year-on-year in the first six months of 2022. The number of inpatients rose by 11.9 % to 51,891 patients while the occupancy rate increased by 6.6 percentage points to 78.1 %. For the 2022 financial year, the Management Board continues to expect Group sales and Group operating result to be higher than in the previous year. Business performance covers only part of the cost increases "We call on politicians to act in the interests of patients and this includes creating timely compensation for the costs of protective measures and testing as well as for massively rising material and personnel costs in the acute and rehabilitation sector," said Dr. Joachim Ramming, CEO of MEDICLIN. In the first six months of 2022, Group sales of EUR 355.3 mill. were up EUR 32.2 mill. or 10.0 % on the first six months of 2021. The Group operating result of EUR 6.6 mill. was EUR 20.0 mill. above the first six months of 2021. Group EBIT was burdened in particular by higher material expenses. The rise in raw materials and consumables used exceeded the prior-year value by EUR 6.5 mill. or 11.1 %. Due to the lower headcount, staff costs rose only moderately by EUR 0.9 mill. or 0.4 %. “With an increase of EUR 4.4 million, the largest item in the cost increases was the expenditure on energy," reported Tino Fritz, CFO of MEDICLIN. Gross capital expenditure amounted to EUR 9.5 mill. in the first six months of 2022 (H1 2021: EUR 8.6 mill.). Cash and cash equivalents as of 30 June 2022 amounted to EUR 102.2 mill. (31.12.2021: EUR 119.5 mill.). No more benefits under the protective shield to manage the COVID-19 pandemic in the second half of 2022. It is currently questionable whether benefit payments will be resumed. "The Covid-19 pandemic is not over. Furthermore, protective measures such as testing as well as the wearing of masks and protective clothing are part of everyday hospital life. This requires time, a sense of responsibility and also money. In order to continue to provide our patients with the best possible care, the rehabilitation sector urgently needs further financial compensation," said Dr. York Dhein, COO of MEDICLIN and responsible, among other things, for the Rehabilitation segment. Outlook – no changes to forecast for the 2022 financial year In the second half of 2022, high energy costs and rising general material costs must be expected. MEDICLIN is already making use of energy savings opportunities without compromising on quality and hygiene requirements as well as medical, therapeutic and nursing performance. Given the current situation, it is therefore all the more crucial that demand continue to rise in order to at least partially compensate for the cost hike through better capacity utilisation and the corresponding higher sales. With regard to the previous forecast for the 2022 financial year, the Management Board continues to assume that the Group's sales and earnings will be higher than in the previous year. The forecast, however, is subject to the proviso that the economic performance in Germany is not massively and sustainably impacted by the current overall conditions. As MEDICLIN belongs to a system-relevant sector, the delivery and supply of gas is currently secure. The interim report as of June 30, 2022 is available from today under www.mediclin.de in German and English.
About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510) MEDICLIN includes 35 clinics, seven care facilities and eleven medical care centers. The Group has around 8,350 beds/care places and employs around 10,200 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs. MEDICLIN ─ a company of the Asklepios Group.
29.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MediClin AG |
Okenstraße 27 | |
77652 Offenburg | |
Germany | |
Phone: | +49 (0)781 488-326 |
Fax: | +49 (0)781 488-184 |
E-mail: | alexandra.muehr@mediclin.de |
Internet: | www.mediclin.de |
ISIN: | DE0006595101 |
WKN: | 659510 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1409333 |
End of News | DGAP News Service |
|
1409333 29.07.2022
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.